GlassScriptPhysician profile
Kavitha V Kosuri
NPI 1215981766
$1,941.62
in general payments reported to CMS, 2019-2025
31 companies · $593 in 2025
The $593 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $185 · 2020: $18.39 · 2021: $52.36 · 2022: $381 · 2023: $462 · 2024: $250 · 2025: $593.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,305.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,305.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $267.13 | 2020-2023 | Tukysa |
| Daiichi Sankyo INC. | $197.11 | 2023-2025 | Enhertu |
| Merck Sharp & Dohme LLC | $129.92 | 2019-2025 | Keytruda |
| Gilead Sciences, INC. | $121.86 | 2021-2025 | Trodelvy |
| E.R. Squibb & Sons, L.L.C. | $117.82 | 2022-2025 | Opdivo |
| Emd Serono, INC. | $115.36 | 2019 | |
| Genzyme Corporation | $97.96 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $89.13 | 2022-2025 | Imfinzi, Enhertu |
| Bayer Healthcare Pharmaceuticals INC. | $67.61 | 2024-2025 | |
| Celgene Corporation | $65.00 | 2022-2023 | Reblozyl |
| Kite Pharma, INC. | $64.67 | 2022-2025 | Yescarta |
| Genentech USA, INC. | $60.14 | 2019-2023 | Tecentriq, Polivy |
| Glaxosmithkline, LLC. | $50.88 | 2021-2025 | Ojjaara |
| Puma Biotechnology, INC. | $49.79 | 2024-2025 | |
| Incyte Corporation | $46.80 | 2024-2025 | Jakafi, Niktimvo, Monjuvi |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $41.05 | 2023 | Epkinly, Imbruvica |
| Janssen Biotech, INC. | $40.42 | 2019-2025 | Talvey, Darzalex |
| Novartis Pharmaceuticals Corporation | $37.49 | 2019-2025 | |
| Array Biopharma INC | $35.03 | 2025 | Braftovi, Lorbrena, Xalkori |
| Taiho Oncology, INC. | $33.64 | 2024-2025 | |
| Tempus Ai, INC | $26.89 | 2024 | |
| Sumitomo Pharma America, INC. | $26.10 | 2023 | Orgovyx |
| Legend Biotech USA INC. | $23.60 | 2025 | Carvykti |
| Karyopharm Therapeutics INC. | $22.80 | 2025 | Xpovio |
| Mirati Therapeutics, INC. | $20.64 | 2023 | Krazati |
| Corcept Therapeutics | $20.23 | 2025 | Korlym |
| Pfizer INC. | $18.18 | 2024 | |
| Astellas Pharma US INC | $16.93 | 2025 | Vyloy |
| Cti Biopharma Corp. | $14.95 | 2023 | Vonjo |
| Adc Therapeutics America, INC. | $11.40 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kavitha Kosuri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.